RGFP966
Catalog #
27643-1
$175
*
●
●
Purchase
Description
RGFP966 is specific for HDAC3, with an IC50 of 0.08 µM and no effective inhibition of any other HDAC at concentrations up to 15 µM.
●
Synonyms
(E)-N-(2-amino-4-fluorophenyl)-3-(1-cinnamyl-1H-pyrazol-4-yl)acrylamide
●
Product Data Gallery
Product Info
Storage and Usage
Citations
Target(s)
HDAC3
Formula
C21H19FN4O
MW
362.4 Da
Solubility
Soluble in DMSO
CAS Registry #
1357389-11-7
Background
RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to Western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression.
References
1. Wells CE, et al. PLoS One. 2013 Jul 22;8(7):e68915.
2. Malvaez M, et al. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52.
2. Malvaez M, et al. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52.